Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583505 | 0.96 | MCL1 (0.38) | MCL1TERTDPP4POLBKMT2A | |
| SCHEMBL583094 | 0.83 | PAOX (0.39) | MCL1DPP4POLBKMT2AMEN1 | |
| SCHEMBL1790228 | 0.80 | — | — | |
| SCHEMBL2016408 | 0.80 | MCL1 (0.54) | MCL1TERTDPP4POLB | |
| Hydrochloric Acid SCHEMBL10795924 | 0.78 | MCL1 (0.50) | MCL1TERTDPP4POLBKMT2A | |
| SCHEMBL7746727 | 0.77 | PSMB5 (0.44) | MCL1KMT2AMEN1 | |
| SCHEMBL582966 | 0.76 | — | — | |
| SCHEMBL21153346 | 0.76 | MCL1 (0.48) | MCL1TERTDPP4POLBKMT2A | |
| SCHEMBL293808 | 0.75 | — | — | |
| SCHEMBL24393751 | 0.74 | MCL1 (0.37) | MCL1TERTDPP4POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| EP-2854815-B1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMA CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170196877-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9669075-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9636382-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-5922711-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | MCL1 2782/4885TERT 2487/4885DPP4 94/4885 |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | MCL1 2782/4885TERT 2487/4885DPP4 94/4885 |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | MCL1 2782/4885TERT 2487/4885DPP4 94/4885 |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | MCL1 2782/4885TERT 2487/4885DPP4 94/4885 |
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | MCL1 2782/4885TERT 2487/4885DPP4 94/4885 |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | MCL1 2782/4885TERT 2487/4885DPP4 94/4885 |
| US-20170196877-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | MCL1 2782/4885TERT 2487/4885DPP4 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.